Corrosion Damage in Reinforced Concrete identified by AE

Deterioration and damage in reinforced concrete (RC) have been reported world-wide.   One of critical causes is a salt attack.  Thus, monitoring against corrosion damageis a key issue.  To identify the onset of corrosion and the nucleation of corrosion-induced cracks due to expansion of corrosion products, continuous acoustic emission (AE) monitoring is available.   SiGMA (Simplified Green’s functions for Moment tensor Analysis) procedure is applied to AE waveforms to identify source kinematics of micro-cracks in the corrosion process.  Results show that the onset of corrosion and the nucleation of corrosion-induced cracks in RC are visually located.  Further, corrosion damage due to the expansion of corrosion products is quantitatively identified

慢性疾患のある小学校就学児の学校生活における保護者および教師の不安・困難感に関する文献検討

研究資

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Background and Objectives: In recent years, the effectiveness of chemotherapy after immune checkpoint inhibitor administration has attracted attention in various cancers, including head and neck cancers. However, individual assessments of the administered chemotherapy regimens are insufficient. This study aimed to evaluate the efficacy and safety of chemotherapy after immune checkpoint inhibitor administration in recurrent metastatic head and neck cancer by focusing on a single regimen. Materials and Methods: We retrospectively reviewed clinical and radiological data from the medical records of 18 patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who received systemic chemotherapy with weekly cetuximab and paclitaxel (Cmab + PTX) after progression following immune checkpoint inhibitor (ICI) therapy. The objective response rate (ORR) and disease control rate (DCR) were assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Adverse events (AEs) were recorded using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Results: In all patients, the ORR, DCR, median PFS, and median OS were 44.4%, 72.2%, 3.8 months, and 9.6 months, respectively. Regarding AEs, three patients developed grade 3 neutropenia. Grade 3 anemia, paronychia, asthenia, and peripheral neuropathy were observed in one patient each. There were no treatment-related deaths. Conclusions: Cmab + PTX was shown to maintain high efficacy and acceptable safety for R/M HNSCC that progressed after ICI therapy. Further research is needed to establish optimal treatment sequences and drug combinations for recurrent R/M HNSCC

2020 年におけるCOVID-19 の状況と看護学部の臨地実習への対応

教育活動報